In breast cancer patients with germline pathogenic BRCA1/2 mutations, cancer cells harbor homologous recombination repair deficiency (HRD) due to malfunction of BRCA1 or BRCA2 protein in DNA damage repair. Here, BRCA2 is linked to hypoparathyroidism-retardation-dysmorphism syndrome.